Objectives: The present study evaluated the impact of a commercially available explainable AI algorithm in augmenting the ability of clinicians to identify lung cancer on chest X-rays (CXR). Design: This retrospective study evaluated the performance of 11 clinicians for detecting lung cancer from chest radiographs, with and without assistance from a commercially available AI algorithm (red dot, Behold.ai) that predicts suspected lung cancer from CXRs. Clinician performance was evaluated against clinically confirmed diagnoses. Setting: The study analysed anonymised patient data from an NHS hospital; the dataset consisted of 400 chest radiographs from adult patients (18 years and above) who had a CXR performed in 2020, with corresponding clinical text reports. Participants: A panel of readers consisting of 11 clinicians (consultant radiologists, radiologist trainees and reporting radiographers) participated in this study. Main outcome measures: Overall accuracy, sensitivity, specificity and precision for detecting lung cancer on CXRs by clinicians, with and without AI input. Agreement rates between clinicians and performance standard deviation were also evaluated, with and without AI input. Results: The use of the AI algorithm by clinicians led to an improved overall performance for lung tumour detection, achieving an overall increase of 17.4% of lung cancers being identified on CXRs which would have otherwise been missed, an overall increase in detection of smaller tumours, a 24% and 13% increased detection of stage 1 and stage 2 lung cancers respectively, and standardisation of clinician performance. Conclusions: This study showed great promise in the clinical utility of AI algorithms in improving early lung cancer diagnosis and promoting health equity through overall improvement in reader performances, without impacting downstream imaging resources.
翻译:目标:本研究评估了商业上可提供解释的AI算法在提高临床医生在胸X射线(CXR)中识别肺癌的能力方面的影响。设计:这项追溯性研究评估了11名临床医生通过胸前射线检查肺癌的绩效,有11名临床医生(咨询放射师、放射师受训人员和报告放射师)参与这项研究,有11名商业上可得到的AI算法(red dot, afail.ai),该算法预测CXRs的肺癌疑似病例。临床性能根据临床确认的诊断进行了评估。设置:该研究分析了NHS医院医院的匿名下流病人数据;数据集包括400名成人病人(18岁及以上)的胸透镜,这些病人在2020年接受了CXR(CX),并附有相应的临床文本报告。 参与者:由11名临床医师(咨询师、放射师受训人员和报告放射师)组成的一个读者小组参加了这项研究。主要结果衡量尺度:诊所在C.%的肺癌检测中测算结果显示,在13个肺癌的早期测算结果中,通过测算结果显示C.